key: cord-1052322-jdnvzois
authors: Yang, Sidi; Cao, Liu; Xu, Wenting; Xu, Tiefeng; Zheng, Birong; Ji, Yanxi; Huang, Siyao; Liu, Lihong; Du, Jie; Peng, Hong; Zhang, Huan; Chen, Jingdiao; Ke, Bixia; Zheng, Huanying; Deng, Xiaoling; Li, Chunmei; Guo, Deyin
title: Comparison of model‐specific histopathology in mouse models of COVID‐19
date: 2022-04-13
journal: J Med Virol
DOI: 10.1002/jmv.27747
sha: 15ebd65bfbd9084e6bc7023db4822b69c5acc4a3
doc_id: 1052322
cord_uid: jdnvzois

A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has been identified as the causative agent of the current coronavirus disease 2019 pandemic. Development of animal models that parallel the clinical and pathologic features of disease are highly essential to understanding the pathogenesis of SARS‐CoV‐2 infection and the development of therapeutics and prophylactics. Several mouse models that express the human angiotensin converting enzyme 2 (hACE2) have been created, including transgenic and knock‐in strains, and viral vector‐mediated delivery of hACE2. However, the comparative pathology of these mouse models infected with SARS‐CoV‐2 are unknown. Here, we perform systematic comparisons of the mouse models including K18‐hACE2 mice, KI‐hACE2 mice, Ad5‐hACE2 mice and CAG‐hACE2 mice, which revealed differences in the distribution of lesions and the characteristics of pneumonia induced. Based on these observations, the hACE2 mouse models meet different needs of SARS‐CoV‐2 researches. The similarities or differences among the model‐specific pathologies may help in better understanding the pathogenic process of SARS‐CoV‐2 infection and aiding in the development of effective medications and prophylactic treatments for SARS‐CoV‐2.

pathogenesis, and to develop new therapies and preventative treatments against COVID-19. One major approach in achieving these goals has been large-scale screening in preclinical small animal models, particularly mice. As with SARS-CoV, SARS-CoV-2 enter host cells via the interaction of the viral Spike (S) protein with human angiotensin converting enzyme 2 (hACE2). 3 Unfortunately, mouse ortholog of ACE2 is incompatible with SARS-CoV-2 S protein, and therefore, typical wild-type mouse strains are not susceptible to SARS-CoV-2. Overcoming this limitation requires either mouse adaptation of the virus, or heterologous expression of hACE2 in mice.

Several mouse models that express the hACE2 gene were created including transgenic and knock-in strains, as well as viral vector-mediated delivery of hACE2. Transgenic models include hACE2 expression under the control of the human cytokeratin (K18) epithelial cell promoter (K18-hACE2), or the synthetic CAG composite promoter (CAG-hACE2) driving high levels of expression in eukaryotic cells. 4, 5 The knock-in model was generated by knocking-in hACE2 (KI-hACE2) into endogenous mouse Ace2 loci. 6 The vector-mediated delivery of hACE2 has been successfully established, which adopts a recombinant human adenovirus type 5-expressing hACE2 (Ad5-hACE2) under the CMV promoter. 7 Although the hACE2 mice as described above fully support SARS-CoV-2 replication, the pathogenesis does not accurately model the disease course seen in humans. 8 Therefore, choosing a suitable mouse model which can replicate the human disease, or some aspects thereof, as closely as possible, is more befitting to us to understand the pathogenesis of SARS-CoV-2 infection.

Histopathology has initially been and is still being used today to diagnose infections in humans or animals. 9 It has been a powerful, reliable, and reproducible tool to better understand disease pathogenesis and evaluate novel treatments of the current virus outbreaks. 10 In addition to qualitative diagnoses, semiquantitative assessment of lesions for histopathology are a common approach to assess all preclinical models used for the development of novel treatment strategies and acceptance by regulatory agencies. 11, 12 Previous studies have revealed that the most pathological changes caused by SARS-CoV-2 were interstitial pneumonia in different hACE2 mice. 4, 6, 13, 14 However, pathological description for SARS-CoV-2 murine pneumonia existing to date are very superficial, addressing only a few, rather unspecific parameters. More importantly, they hardly allow for a differentiating perspective between distinct types of hACE2 mice. Hence, there is an urgent need for more precise and model-specific parameters to allow for an accurate description and semiquantitative evaluation of lung alterations in hACE2 mice. Here, we systematically describe and compare the histopathological changes at acute stage of the four types of SARS-CoV-2 infection hACE2 mouse models which include K18-hACE2 mice, KI-hACE2 mice, Ad5-hACE2 mice and CAG-hACE2 mice. Ad5-hACE2 mice were established as previously described. 14 Mice were provided with sterile water and chow ad libitum and acclimatized for at least 1 week before experimental manipulation.

The Biosafety Committee of Sun Yat-sen University approved work with infectious SARS-CoV-2 virus strains under BSL3 conditions. All sample inactivation was performed according to Biosafety Committee of Sun Yat-sen University approved standard operating procedures for removal of specimens from high containment. All in vivo studies were performed in accordance with the animal experiment protocol approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University. All mice were maintained in a specific pathogen-free animal facility at Sun Yat-sen University. 

The lung tissues were processed through routine histologic methods.

In brief, the lung tissues were fixed in 10% neutral buffered formalin for 24 h at room temperature, embedded in paraffin, and cut into 4-μm thick sections. The sections were then subjected to H&E staining to show lesions. All photomicrographs were automatically digitized using the Aperio CS2 slide scanner (Leica Biosystems Imaging Inc.) and image files were generated using the NDP.view2

Viewing software.

The evenly distributed whole-organ horizontal sections throughout the entire lungs were microscopically evaluated to assess the distribution and character of pathologic alterations: −, absent, within normal limits; +, minor, approximately 25%-50% or less of corresponding pathological changes are observed; ++, major, over 50% of corresponding pathological changes are noted. All examinations were performed by trained veterinary experimental pathologists. (Table 1 ).

K18-hACE2 mice, also known as B6.Cg-Tg (K18-ACE2) 2Prlmn/J, were first generated by McCray and colleagues in 2007. 15 hACE2 expression in K18-hACE2 mice is driven by human cytokeratin gene promoter that is active in the airway epithelial cells. 15 Recent research indicates that intranasal inoculation with SARS-CoV-2 caused the development of pneumonia, which is consistent with our results. 4 Here, we evaluated the lung histopathological changes at 3 dpi ( Figure 1A ). All SARS-CoV-2-infected mice exhibited multifocal, interstitial pneumonia ( Figure 1B Moreover, pronounced hemorrhage within alveolar spaces, and interstitial, and prominent perivascular lymphocytic cuffing was a characteristic change ( Figure 1H) . A moderate necrosis of bronchial epithelial cell was observed whereas no alveolar wall necrosis was present. The histopathology of lung tissue showed that the alveolar structure of the K18-hACE2 control group was intact ( Figure 1I) 

The KI-hACE2 mice, which was generated by CRISPR/Cas9 knock-in technology by replacing the endogenous mouse ACE2 (mACE2) with the human ACE2. 6 H&E staining showed that mouse lungs displayed a diffusely distributed interstitial pneumonia at 4 dpi with SARS-CoV- 

We used adenovirus constructs to transduce C57BL/6 mice by intranasal inoculation of 2.5 × 10 8 FFU of Ad5-ACE2. Five days posttransduction, mice were infected with SARS-CoV-2. At 2 dpi, examination of lung tissues from mice demonstrated in multifocally extensive interstitial pneumonia but predominantly located near the lung hilus ( Figure 3A ). Similar to K18-hACE2 transgenic model, the peribranchial, alveolar and perivascular areas were predominantly infiltrated by lymphocytes, macrophages, and neutrophils. Unlike K18-hACE2 model, perivascular edema and vascular thrombosis was hardly observed, but protein-rich alveolar edema ( Figure 3D ) was present albeit to a lesser extent. Here, prominent perivascular lymphocytic cuffing, vasculitis as well as alveolar wall necrosis were observed ( Figure 3E ). Bronchial epithelial cells were moderately necrotic ( Figure 3F ), and type II alveolar epithelial cells were moderately hyperplasia. Furthermore, a small portion of venous blood vessels had fibrinoid degeneration ( Figure 3G ) and, albeit to a much lesser extent, areas of hemorrhage within alveoli and interstitium were present. Figure 3H as a lung histology of Ad5-hACE2 control mice.

In parallel, we used an advanced newly developed hACE2-transgenic C57BL/6 mouse model CAG-hACE2-IRES-Luc-Tg, which express hACE2 under the CAG promoter at high levels of gene expression. 16 To further evaluate the lung histopathological changes, mice were euthanized at 3 dpi, and lung tissues were collected to H&E staining ( Figure 4A ). Histologically, mice lungs displayed a diffusely distributed interstitial pneumonia ( Figure 4B) Figure 4F as a lung histology of CAG-hACE2 control mice.

In the present study, we provide a detailed descriptive overview of histopathological features at acute stage of SARS-CoV-2 infection in four hACE2 mouse models. The models employed in this study were well established, which had been repeatedly confirmed in our previous works and also successfully used in previous studies from other laboratories. 4, 6, 13, 14, 17, 18 Our model-specific description parameters (Table 2 ) are helpful to distinguish histopathological features of different hACE2 mouse models accurately. The potential of these parameters for future evaluation of hACE2 mouse models is extensive.

Comparing the different staining in the four hACE2 mouse models, varying degrees of inflammation, especially interstitial pneumonia, and varying degrees of lesions, including inflammatory cell infiltration, pulmonary edema, hemorrhaging, necrosis of the bronchial epithelial cells, and hyperplasia of type II alveolar epithelial cells were observed. In the lungs of K18-hACE2 mice, exudative pathological changes were found, exhibiting pulmonary edema, inflammatory cell infiltration, hemorrhaging, fibrinous exudates and perivascular lymphocytic cuffing, suggesting acute pneumonia. This is in consistence with the previous study that have also reported that K18-hACE2 mice exhibited potentially lethal disease. 19 Additionally, we found that the prominent inflammatory cells in the CAG-hACE2 mice was different. In our study, the diffuse infiltration of numerous In conclusion, we established animal models of SARS-CoV-2 infection using K18-hACE2 mice, KI-hACE2 mice, Ad5-hACE2 mice and CAG-hACE2 mice. We have uncovered a model-specific lung lesion with characteristic histopathology, which provides a framework that may help in better understanding the pathogenic process of SARS-CoV-2 infection and aiding in the development of effective medications and prophylactic treatments for SARS-CoV-2.

Deyin Guo: conceived and planned the overall structure of the article.

Sidi Yang and Liu Cao: contributed to development of methodology T A B L E 2 Model-specific pathological changes in mouse models of SARS-CoV-2 infection 

COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19

COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice

Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor

A mouse model of SARS-CoV-2 infection and pathogenesis

Genetically modified mouse models to help fight COVID-19

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology-a systematic review

Acute Lung Injury in Animals Study, G. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals

A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: lessons learned from multiple discordant methodologies in the setting of colorectal cancer

Spectrum of pathogen-and model-specific histopathologies in mouse models of acute pneumonia

Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2

Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment

Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus

The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variants

Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation

K18-hACE2 mice develop respiratory disease resembling severe COVID-19

SARS-CoV-2 causes lung infection without severe disease in human ACE2 knock-in mice

Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States

A cohort autopsy study defines COVID-19 systemic pathogenesis

Lung histopathology in coronavirus disease 2019 as compared with severe acute respiratory sydrome and H1N1 influenza: a systematic review

Comparative pathology of rhesus macaque and common marmoset animal models with Middle East respiratory syndrome coronavirus

The authors declare no conflicts of interest.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

http://orcid.org/0000-0002-8297-0814